Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
12:00pm, Friday, 27'th Mar 2020
PHILADELPHIA, March 27, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
DZ Bank likes Medtronic in premarket analyst action
11:14am, Wednesday, 25'th Mar 2020
Menlo Therapeutics (NASDAQ:MNLO) initiated with Overweight rating and $8 (161% upside) price target at Barclays.Molecular Templates (NASDAQ:MTEM) initiated with Buy rating and $19 (43% upside) price t
Blair likes Incyte in premarket analyst action
11:53am, Tuesday, 24'th Mar 2020
Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares u
Passage Bio (PASG) Initiated with a Buy at Cowen & Co.
09:41am, Tuesday, 24'th Mar 2020
Passage Bio (PASG) received a Buy rating from Cowen & Co. analyst Yaron Werber today. The company's shares closed last Monday at $12.06. According to
Passage Bio (PASG) Initiated with a Buy at Cowen & Co.
09:41am, Tuesday, 24'th Mar 2020
Passage Bio (PASG – Research Report) received a Buy rating from Cowen & Co. analyst Yaron Werber today. The company’s
13D Filings
01:18am, Saturday, 14'th Mar 2020
Activists file with the SEC on Synalloy, Passage Bio, LKQ, PDL BioPharma, and Quantum
Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
08:30pm, Monday, 09'th Mar 2020
PHILADELPHIA, March 09, 2020 -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturu
REFILE-Bankers try to keep IPO party going amid coronavirus market jitters
10:33pm, Thursday, 05'th Mar 2020
Some of the best seats at the Boston TD Garden arena's Tuesday night basket...
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
Passage Bio Appoints Athena Countouriotis to Board of Directors
01:00pm, Thursday, 05'th Mar 2020
Passage Bio, Inc. (PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Athena Countouri
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
12:37pm, Wednesday, 04'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
12:51pm, Tuesday, 03'rd Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) * Forty Seven Inc (NASDAQ: FTSV)( announced a dea
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More
02:52pm, Friday, 28'th Feb 2020
Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making
Passage Bio Announces Pricing of Initial Public Offering
12:25am, Friday, 28'th Feb 2020
PHILADELPHIA, Feb. 27, 2020 -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system.
